UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

Form 6-K

 

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of November, 2021

Commission File Number                         

 

 

Kazia Therapeutics Limited

(Translation of registrant’s name into English)

 

 

Three International Towers Level 24 300 Barangaroo Avenue Sydney NSW 2000

(Address of principal executive office)

 

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F  ☑             Form 40-F   ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):  ☐

Note: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):  ☐

Note: Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant’s “home country”), or under the rules of the home country exchange on which the registrant’s securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant’s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.

Indicate by check mark if the registrant by furnishing the information contained in this form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934. Yes  ☐     No  ☑

If “yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b)

 

 

 


SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Kazia Therapeutics Limited (Registrant)

Kate Hill

Kate Hill

Company Secretary

Date 10 November 2021


LOGO

ASX RELEASE

10 November 2021

KAZIA ANNUAL GENERAL MEETING RESULTS

Sydney, 10 November 2021 – Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to announce the results of its Annual General Meeting of shareholders.

All resolutions were carried. The vote totals are attached.

[ENDS]

About Kazia Therapeutics Limited

Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA) is an oncology-focused drug development company, based in Sydney, Australia.

Our lead program is paxalisib, a brain-penetrant inhibitor of the PI3K / Akt / mTOR pathway, which is being developed to treat glioblastoma, the most common and most aggressive form of primary brain cancer in adults. Licensed from Genentech in late 2016, paxalisib commenced recruitment to GBM AGILE, a pivotal study in glioblastoma, in January 2021. Eight additional studies are active in various forms of brain cancer. Paxalisib was granted Orphan Drug Designation for glioblastoma by the US FDA in February 2018, and Fast Track Designation for glioblastoma by the US FDA in August 2020. In addition, paxalisib was granted Rare Pediatric Disease Designation and Orphan Designation by the US FDA for DIPG in August 2020.

Kazia is also developing EVT801, a small-molecule inhibitor of VEGFR3, which was licensed from Evotec SE in April 2021. Preclinical data has shown EVT801 to be active against a broad range of tumour types and has provided compelling evidence of synergy with immuno-oncology agents. A phase I study commenced recruitment in November 2021.

For more information, please visit www.kaziatherapeutics.com or follow us on Twitter @KaziaTx.

This document was authorized for release to the ASX by James Garner, Chief Executive Officer, Managing Director.


KAZIA THERAPEUTICS LIMITED

2021 Annual General Meeting

Wednesday, 10 November 2021

Results of Meeting

The following information is provided in accordance with section 251AA(2) of the Corporations Act 2001 (Cth) and ASX Listing Rule 3.13.2.

 

Resolution details

   Instructions given to validly appointed proxies
(as at proxy close)
   Number of votes cast on the poll
(where applicable)
   Resolution
Result

Resolution

   Resolution
Type
   For    Against    Proxy’s
Discretion
   Abstain    For    Against    Abstain*    Carried /
Not Carried
1 Adoption of Remuneration Report   

Ordinary

   49,207,558    3,878,538    235,430    577,684    49,828,789    3,878,538    577,684   

Carried

   92.29%    7.27%    0.44%    92.78%    7.22%
2 Re-Election of Iain Ross   

Ordinary

   54,570,330    1,386,017    267,430    62,545    55,223,561    1,386,017    62,545   

Carried

   97.05%    2.47%    0.48%    97.55%    2.45%
3 Adoption of Employee Share Option Plan   

Ordinary

   48,959,855    4,330,036    235,430    1,825,140    49,581,086    4,330,036    1,825,140   

Carried

   91.47%    8.09%    0.44%    91.97%    8.03%
4 Grant of up to 1,000,000 FY20 option to Dr James Garner   

Ordinary

   48,084,146    5,198,416    236,480    830,168    48,706,427    5,198,416    830,168   

Carried

   89.84%    9.72%    0.44%    90.36%    9.64%
5 Grant of up to 1,500,000 FY20 option to Dr James Garner   

Ordinary

   48,840,011    4,440,721    235,430    833,048    49,461,242    4,440,721    833,048   

Carried

   91.26%    8.30%    0.44%    91.76%    8.24%
6 Ratification of prior issue of Placement Shares   

Ordinary

   53,576,061    2,137,610    247,430    325,221    54,134,292    2,137,610    400,221   

Carried

   95.74%    3.82%    0.44%    96.20%    3.80%
7 Approval of Additional Placement capacity under Listing Rule 7.1A   

Special

   51,779,004    3,733,280    267,434    506,604    52,432,239    3,733,280    506,604   

Carried

   92.82%    6.70%    0.48%    93.35%    6.65%

 

*

Votes cast by a person who abstains on an item are not counted in calculating the required majority on a poll.

Kazia Therapeutics (NASDAQ:KZIA)
Historical Stock Chart
From Jun 2024 to Jul 2024 Click Here for more Kazia Therapeutics Charts.
Kazia Therapeutics (NASDAQ:KZIA)
Historical Stock Chart
From Jul 2023 to Jul 2024 Click Here for more Kazia Therapeutics Charts.